Plus Therapeutics Company Insiders

Plus Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.6939) % which means that it has lost $0.6939 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.225) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics' management efficiency ratios could be used to measure how well Plus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 10.37 in 2024, whereas Return On Tangible Assets are likely to drop (1.27) in 2024. Total Current Assets is likely to climb to about 17.1 M in 2024, whereas Total Assets are likely to drop slightly above 10.8 M in 2024. Common Stock Shares Outstanding is likely to climb to about 3.3 M in 2024, whereas Net Loss is likely to drop (24.5 M) in 2024.

Plus Therapeutics Workforce Comparison

The company has Profit Margin (PM) of (2.4) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.89) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.89.

Plus Therapeutics Insider Trading

Plus Therapeutics Notable Stakeholders

The success or failure of an entity such as Plus Therapeutics often depends on how effective the management is. Plus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Plus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Plus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Plus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Plus Therapeutics. Check Plus Therapeutics' Beneish M Score to see the likelihood of Plus Therapeutics' management manipulating its earnings.

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.